ESTRO 2025 - Abstract Book

S838

Clinical - Gynaecology

ESTRO 2025

3 (19,38), CTV-T

(3,9), CTV-T HR 27cm

HR D 90% 92Gy (91,95) EQD2 10 ; median D 2cm³ EQD2 3 for bladder 75Gy (69,80), rectum

58Gy (53,63), sigmoid 62Gy (57,67), bowel 58Gy (50,66) , recto-vaginal point 60Gy (56,64). Overall, 301 patients recurred – 95 local, 66 pelvic-nodal, 142 pelvic (local+pelvic nodal), 84 para-aortic, 120 regional nodal, 194 local+regional nodal, 181 distant (beyond para-aortic). 217 patients died, 176 from cancer (Table Figure). Late life-threatening (G4) Gastro-Intestinal (GI), Genito-Urinary (GU), Vagina (Vag) morbidity was 1%. 2 patients died from treatment. Multiple hypotheses on treatment planning/performance 2,3 and clinical outcome 2,3 were confirmed (Text-Table).